Activating frataxin expression by repeat-targeted nucleic acids

Nature Communications

Volumn 7, Issue , 2016, Pages

  Li, Liande ^a   Matsui, Masayuki ^a   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; DNA; FRATAXIN; GENOMIC DNA; LOCKED NUCLEIC ACID; MESSENGER RNA; RNA; SMALL INTERFERING RNA; ARGONAUTE PROTEIN; EIF2C2 PROTEIN, HUMAN; IRON BINDING PROTEIN; NUCLEIC ACID;

CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENOMICS; MUTATION; NUCLEIC ACID; PROTEIN;

ARTICLE; CONTROLLED STUDY; FRATAXIN GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSFECTION; HETEROCHROMATIN; HISTONE ACETYLATION; HISTONE MODIFICATION; IMMUNOPRECIPITATION; NUCLEIC ACID STRUCTURE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; RNA STRUCTURE; RNA SYNTHESIS; TRINUCLEOTIDE REPEAT; UPREGULATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FIBROBLAST; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTRON; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ARGONAUTE PROTEINS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; FIBROBLASTS; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; INTRONS; IRON-BINDING PROTEINS; NUCLEIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84956900108     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10606     Document Type: Article

References (45)

1. Pandolfo, M. Friedreich ataxia: the clinical picture. J. Neurol. 256, 3-8 (2009).
2. Collins, A. Clinical neurogenetics: ataxia. Neurol. Clin. 31, 1095-1120 (2013).
3. Marmolino, D. Friedreich's ataxia: past, present and future. Brain Res. Rev. 67, 311-330 (2011).
4. Sandi, C., Sandi, M., Virmouni, S. A., Al-Mahdawi, S., Pook, M. A. Epigenetic-based therapies for Friedreich ataxia. Front. Genet. 5, 1-12 (2014).
5. Richardson, T. E., Kelly, H. N., Yu, A. E., Simpkins, J. W. Therapeutic strategies in Friedreich's ataxia. Brain Res. 1514, 91-97 (2013).
6. Gottesfeld, J. M., Rusche, J. R., Pandolfo, M. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J. Neurochem. 126, 147-154 (2013).
7. Greene, E., Mahishi, L., Entezam, A., Kumari, D., Usdin, K. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res. 35, 3383-3390 (2007).
8. Al-Mahdawi, S. et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet. 17, 735-746 (2008).
9. Kumari, D., Lokanga, R., Yudkin, D., Zhao, X.-N., Usdin, K. Chromatin changes in the development and pathology of the Fragile X-associated disorders and Friedreich ataxia. Biochim. Biophys. Acta 1819, 802-810 (2012).
10. Sandi, C. et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 42, 496-505 (2011).
11. Chan, P. K. et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum. Mol. Genet. 22, 2662-2675 (2013).
12. Libri, V. et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet 384, 504-513 (2014).
13. Soragni, E. et al. Epigenetic therapy for Friedreich ataxia. Ann. Neurol. 76, 489-508 (2014).
14. Sahdeo, S. et al. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Hum. Mol. Genet. 23, 6848-6862 (2014).
15. Ohshima, K., Montermini, L., Wells, R. D., Pandolfo, M. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 273, 14588-14595 (1998).
16. Bidichandani, S. I., Ashizawa, T., Patel, P. I. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am. J. Hum. Genet. 62, 111-121 (1998).
17. Grabczyk, E., Mancuso, M., Sammarco, M. C. A persistent RNA. DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, by T7 RNAP in vitro. Nucleic Acids Res. 35, 5351-5359 (2007).
18. Groh, M., Lufino, M. M. P., Wade-Martins, R., Gromak, N. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. N. PLoS Genet. 10, e1004318 (2014).
19. Groh, M., Sliva, L. M., Gromak, N. Mechanisms of transcriptional dysregulation in repeat expansion disorders. Biochem. Soc. Trans. 42, 1123-1128 (2014).
20. Butler, J. S., Napierala, M. Friedreich's Ataxia-a case of aberrant transcription termination. Transcription 6, 33-36 (2015).
21. Li, Y. et al. Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum. Mol. Genet. 24, 6932-6943 (2015).
22. Fiszer, A., Krzyzosiak, W. J. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787-6810 (2014).
23. Hu, J. et al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 53, 4510-4518 (2014).
24. Weinberg, M. S., Morris, K. V. Long non-coding RNA targeting and transcriptional de-repression. Nucleic Acid Ther. 23, 9-14 (2013).
25. Matsui, M. et al. Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res. 41, 10086-10109 (2013).
26. Gagnon, K. T., Li, L., Chu, Y., Janowski, B. A., Corey, D. R. RNAi factors are present and active in human cell nuclei. Cell Rep. 6, 211-221 (2014).
27. Wang, Y. et al. Structure of an argonaute silencing complex with a seedcontaining guide DNA and target RNA duplex. Nature 456, 921-926 (2008).
28. Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2, 551-558 (2006).
29. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
30. Punga, T., Bühler, M. Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol. Med. 2, 120-129 (2010).
31. Campbell, M. A., Wengel, J. Locked versus unlocked nucleic acids (LNA versus UNA): contrasting structures work towards common therapeutic goals. Chem. Soc. Rev. 40, 5680-5689 (2011).
32. Watts, J. K., Corey, D. R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 226, 365-379 (2012).
33. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
34. Sah, D. W. Y., Aronin, N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 121, 500-507 (2011).
35. Skourti-Stathaki, K., Kamieniarz-Gdula, K., Proudfoot, N. J. R-loops induce repressive chromatin marks over mammalian gene terminators. Nature 516, 436-439 (2014).
36. Yu, D. et al. Single-stranded RNAs that function through RNAi are potent and allele-selective inhibitors of huntingtin expression. Cell 150, 895-908 (2012).
37. Chu, Y., Yue, X., Younger, S. T., Janowski, B. A., Corey, D. R. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res. 38, 7736-7748 (2010).
38. Liu, J., Hu, J., Corey, D. R. Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res. 40, 1240-1250 (2012).
39. Schraivogel, D., Meister, G. Import routes and nuclear functions of Argonaute and other small RNA-silencing proteins. Trends Biochem. Sci. 39, 420-431 (2014).
40. Schraivogel, D. et al. Importin-beta facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels. Nucleic Acids Res. 43, 7447-7461 (2015).
41. Allo, M. et al. Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat. Struct. Mol. Biol. 16, 717-724 (2009).
42. Morris, K. V., Chan, S. W., Jacobsen, S. E., Looney, D. J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292 (2004).
43. Li, L. C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA 103, 17337-17342 (2006).
44. Guo, D., Barry, L., Lin, S. S. H., Huang, V., Li, L.-C. RNAa in action: From exception to the norm. RNA Biol. 11, 1221-1225 (2014).
45. Loomis, E. W., Sanz, L. A., Chedin, F., Hagerman, P. J. Transcriptionassociated R-loop formation across the human FMR1 CGG-repeat region. PLoS Genet. 10, e1004294 (2014).